Views: 44 Author: Unibest Industrial Publish Time: 2025-02-03 Origin: Site
Report generated for the week of 2025-02-03 by Unibest Digital Center. Current analysis scope only include the US FDA.
This week, there are 4 drugs in the patent and exclusivity list. They are:
- BRISTOL MYERS SQUIBB CO's SPRYCEL, containing active ingredient DASATINIB
- AMERICAN REGENT INC's INJECTAFER, containing active ingredient FERRIC CARBOXYMALTOSE
- ABBVIE INC's KYBELLA, containing active ingredient DEOXYCHOLIC ACID
- MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC's ZOLINZA, containing active ingredient VORINOSTAT
From BRISTOL MYERS SQUIBB CO; for treating Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia.
Approved in Jun 28, 2006, used as Reference Listed Drug
Approved in May 30, 2008, used as Reference Listed Drug and Reference Standard
Approved in Oct 28, 2010, used as Reference Listed Drug
There are 3 future patent(s) for this application. The earliest expires on 2025-08-04, and the latest expires on 2026-09-28.
Patent No | Patent Expiration Date | Patent Title |
---|---|---|
8680103 | 2025-02-04 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
From ABBVIE INC; a cytolytic agent injected subcutaneously to improve the appearance submental fat.
Approved in Apr 29, 2015, used as Reference Listed Drug and Reference Standard
There are 14 future patent(s) for this application. The earliest expires on 2025-08-03, and the latest expires on 2030-03-02.
Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date | Patent Title |
---|---|---|---|---|
8846066 | U-1690 | METHOD FOR REDUCTION OF SUBMENTAL FAT | 2025-02-08 | Methods and related compositions for reduction of fat and skin tightening |
From AMERICAN REGENT INC; an iron replacement therapy used to treat iron deficiency anemia in children and adults with intolerance or inadequate clinical response to oral iron, and in adult patients who have non-dialysis dependent chronic kidney disease.
Approved in Jul 25, 2013, used as Reference Listed Drug and Reference Standard
Approved in Oct 8, 2020, used as Reference Listed Drug and Reference Standard
Approved in Apr 28, 2021, used as Reference Listed Drug and Reference Standard
Approved in Feb 4, 2022, used as Reference Listed Drug and Reference Standard
In the issue of 2024-11-18, the exclusivity of NEW PATIENT POPULATION for Injectafer has expired.
There are 5 future patent(s) for this application. The earliest expires on 2027-01-08, and the latest expires on 2028-02-15.
Patent No | Patent Expiration Date | Patent Title |
---|---|---|
7612109 | 2025-02-05 | Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
From MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC; for the treatment of cutaneous manifestations in patients with progressive, persistent, or recurrent cutaneous T- cell lymphoma (CTCL) following prior systemic therapies.
Approved in Oct 6, 2006, used as Reference Listed Drug and Reference Standard
There are 3 future patent(s) for this application. The earliest expires on 2026-05-16, and the latest expires on 2028-03-18.
Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date | Patent Title |
---|---|---|---|---|
7399787 | U-892 | TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) | 2025-02-09 | Methods of treating cancer with HDAC inhibitors |
No expirations this week.